Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gluten peptide antigens are specific fragments of gluten proteins that trigger immune responses, particularly in individuals with celiac disease (CeD) and other gluten-related disorders. The most well-characterized immunogenic fragment is the 33-mer peptide from α-gliadin. These peptides can elicit both innate and adaptive immune responses, primarily through activation of CD4+ T cells via HLA-DQ2/DQ8 presentation. Detection of these peptides can be used to monitor dietary adherence in celiac patients. High proline and glutamine content makes these peptides resistant to digestion.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gluten Peptide Antigens (None).